You've probably seen it on your watchlist for years. A constant occupant of the "under $5" screeners. Honestly, the Opko Health stock price has been a bit of a rollercoaster—if that rollercoaster mostly went downward for a decade. As of mid-January 2026, the stock is hovering around **$1.28**.
It’s easy to look at that number and think "zombie company." But if you actually dig into the filings and the recent asset sales, the story is way more nuanced than just another biotech penny stock circling the drain.
Why the Price is Stuck in the Mud
Let’s be real. Investors are exhausted. For years, Opko was the Phillip Frost vehicle—the legendary billionaire who kept buying shares like they were going out of style. While insider buying is usually a "buy" signal, with Opko, it became background noise.
The stock hit a 52-week high of $2.04 and a low of $1.11. That's a massive swing for a company with a nearly $1 billion market cap. The main reason the price hasn't "mooned" yet is simple: trust. The market is waiting for the company to prove it can actually make money consistently without selling off its limbs.
💡 You might also like: Why Your Credit Chips Not Accepted Is Becoming a Real Headache at the Register
The Massive Labcorp Deal and the BioReference Pivot
In late 2025, Opko did something drastic. They sold off a huge chunk of BioReference Health's oncology assets to Labcorp for about $225 million.
This was basically a "clean up the house" move. BioReference was a heavyweight during the COVID-19 testing boom, but as that revenue dried up, the lab business became a bit of an anchor. By selling the oncology segment, Opko pocketed $173.3 million in cash upfront.
- The Result: A leaner BioReference focused on New York and New Jersey.
- The Goal: Stop the bleeding.
- The Cash: They’ve been using that money to buy back shares—about $73.8 million worth so far.
NGENLA: The Pfizer Partnership Nobody Talks About Enough
If you're tracking the Opko Health stock price, you have to track Pfizer. Opko’s big win is NGENLA (somatrogon), a once-weekly growth hormone injection for kids.
It’s already approved in over 40 markets. Pfizer does the heavy lifting on sales, and Opko gets a cut of the gross profits. In the third quarter of 2025 alone, Opko saw $8.8 million from this profit share. It’s not "buy a private island" money yet, but it's growing.
The Pipeline Gamble
Then there's ModeX Therapeutics. This is Opko’s "moonshot" division. They are working on "multispecific" antibodies. Basically, it's a way to hit a virus or a cancer cell from four different angles at once.
- MDX2001: Currently in Phase 1 trials for solid tumors.
- BARDA Contract: They have a massive deal with the government to develop treatments for future pandemics.
- Entera Bio: They are working on an oral GLP-2 tablet. Yes, the "weight loss" category (sorta). It's actually for Short Bowel Syndrome, but it uses similar tech.
What the Analysts are Saying (And Why They Might Be Wrong)
Wall Street is surprisingly optimistic. Or maybe they're just hopeful. The average price target is currently $1.93, with some outliers screaming about a $3.74 or even $8.00 valuation.
Honestly, take those high numbers with a grain of salt. Opko is still losing money. Their EPS is around -$0.24. You can't ignore a negative bottom line forever. However, their Current Ratio is a healthy 3.70, meaning they have plenty of cash to keep the lights on and the labs running for a while.
The Insider Factor
Phillip Frost is still at it. In November 2025, he picked up another $679,000 worth of stock. When the CEO and Chairman keeps throwing his own cash into the pit, it usually means he sees a floor that the rest of us don't. Or he's just incredibly stubborn. Either way, 12 different insiders have been buyers over the last year. Zero sellers. That is a rare stat in the biotech world.
Is it a Buy?
Kinda depends on your stomach for risk. If you’re looking for a safe dividend stock, run away. Opko doesn't pay a dime in dividends. But if you’re looking at the Opko Health stock price as a "deep value" play, there's a case to be made.
They are trading at a significant discount to their book value. If ModeX hits on just one of its Phase 2 trials in 2026, the stock could easily double because the bar is currently set so low.
Real Steps for Investors Now
If you're thinking about jumping in or holding your bag, here is the move.
First, stop looking at the daily chart. It’ll drive you crazy. This stock moves in cents, not dollars.
Second, watch the February 26, 2026 earnings report. That's the big one. We need to see if the BioReference "downsizing" actually resulted in better margins. If they are still losing $40 million a quarter after selling the oncology business, that's a huge red flag.
Third, keep an eye on NGENLA's international rollout. Pfizer is a marketing machine. If those royalty checks start hitting $15 million or $20 million a quarter, the "unprofitability" problem goes away very fast.
Finally, set a limit. Don't let this be the stock that eats your whole portfolio. It’s a classic "speculative" play. If it stays above $1.27 (a key support level), the trend is technically neutral. If it breaks below $1.11, the trapdoor could open.
Basically, Opko is a company in transition. They’ve sold the old stuff to fund the new stuff. Now we just have to see if the new stuff actually works.